Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVN2E6)

• Drug Name: Vinpocetine Drug Info
• Synonyms: Bravinton; Cavinton; Ceractin; Vinpocetinum; Apovincaminic acid ethyl ester; AY 27255; RGH 4405; TCV 3B; V 6383; V6383_SIGMA; AY 27,255; Apovincaminate d'ethyle; Apovincaminate d'ethyle [French]; Cavinton (TN); Cis-Apovincaminic acid ethyl ester; Intelectol (TN); RGH-4405; TCV-3B; Ultra-Vinca; Vinpocetine-ethyl apovincaminate; Vinpocetinum [INN-Latin]; Eburnamenine-14-carboxylic acid ethyl ester; Ethyl apovincamin-22-oate; Vinpocetine [USAN:INN:JAN]; Ethyl (+)-apovincaminate; Vinpocetine (JAN/USAN/INN); Ethyl(+)-cis-apovincaminate; Ethyl apovincaminate, (3alpha,16alpha)-isomer; Ethyl (3alpha,16alpha)-eburnamenine-14-carboxylate; (+)-Apovincaminic acid ethyl ester; (+)-cis-Apovincaminic acid ethyl ester; (3alpha, 16alpha)-Eburnamenine-14-carboxylic acid ethyl ester; 1H-Indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine, eburnamenine-14-carboxylic acid deriv.; 3-alpha,16-alpha-Apovincaminic acid ethyl ester

Indication

Disease Entry	ICD 11	Status	REF
Ischemic stroke	8B11.5Z	Approved	[1]

• Therapeutic Class: Vasodilator Agents
• Cross-matching ID:
  PubChem CID: 443955
  ChEBI ID: CHEBI:32297
  CAS Number: CAS 42971-09-5
  TTD Drug ID: DMVN2E6
  INTEDE Drug ID: DR1697

Molecule-Related Drug Atlas

Drug(s) Targeting Phosphodiesterase 1 (PDE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ITI-214	DM08TH3	Parkinson disease	8A00.0	Phase 1/2	[5]
ZAPRINAST	DMGH3T5	N. A.	N. A.	Terminated	[6]
BIBW-22	DMXIH3Q	Solid tumour/cancer	2A00-2F9Z	Terminated	[7]
isobutylmethylxanthine	DM46F5X	Discovery agent	N.A.	Investigative	[8]
S,S-(2-Hydroxyethyl)Thiocysteine	DMLPAD8	Discovery agent	N.A.	Investigative	[9]
BUFROLIN	DM61F5W	Discovery agent	N.A.	Investigative	[8]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[10]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[11]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[12]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[13]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[14]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[15]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[16]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[17]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[11]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[18]

Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[19]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[20]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[21]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[22]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[22]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[23]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[24]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[25]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[26]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 1 (PDE1)	TTHQENC	NOUNIPROTAC	Inhibitor	[2]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Gene/Protein Processing	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5285).
• [2] Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue. Urology. 2009 Jun;73(6):1397-401.
• [3] Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
• [4] Effects of phosphodiesterase (PDE) inhibitors on human ether-a-go-go related gene (hERG) channel activity. J Appl Toxicol. 2007 Jan-Feb;27(1):78-85. doi: 10.1002/jat.1201.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J Med Chem. 2005 May 19;48(10):3449-62.
• [7] BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells. Mol Pharmacol. 1996 Sep;50(3):482-92.
• [8] A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.
• [9] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [10] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [11] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [12] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [13] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [14] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [15] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [16] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [17] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [18] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [19] Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
• [20] Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
• [21] Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
• [22] Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
• [23] Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
• [24] Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
• [25] Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
• [26] Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.